Asset Details
Do you wish to reserve the book?
NRN1 as a therapeutic target for Alzheimer's disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
NRN1 as a therapeutic target for Alzheimer's disease
Do you wish to request the book?
NRN1 as a therapeutic target for Alzheimer's disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
NRN1 as a therapeutic target for Alzheimer's disease
2026
Overview
INTRODUCTION Neuritin‐1 (NRN1) was identified as a synaptic protein associated with cognitive resilience to Alzheimer's disease (AD). METHODS Target risk score and cell type expression profiles were generated for NRN1 using methods developed by the Emory‐Sage‐SGC‐JAX Target Enablement to Accelerate Therapy Development for Alzheimer's Disease (TREAT‐AD) Center and Seattle Alzheimer's Disease Brain Cell Atlas (SEA‐AD). Antibody characterization was conducted using Western blots and densitometry to assess the relative protein abundances of NRN1 in rodents, humans, and cell models. RESULTS NRN1 has a TREAT‐AD target risk score of 3.29 out of 5. Based on single‐nucleus RNA sequencing from SEA‐AD, NRN1 expression in excitatory neurons tends to decrease with increasing donor pseudo‐progression. Abcam ab64186 polyclonal NRN1 antibody detects NRN1 protein in vitro and in vivo at molecular weights that suggest NRN1 forms a homodimer. NRN1 protein abundance is comparable among controls and primary tauopathy cases, as well as Tau P301S mice and non‐transgenic littermates at 3 and 9 months. DISCUSSION These findings advance the investigation of NRN1 as a therapeutic candidate for AD. Highlights NRN1 is associated with cognitive resilience to AD. Based on snRNA‐seq from SEA‐AD, NRN1 expression in excitatory neurons tends to decrease with increasing donor pseudo‐progression. Abcam ab64186 polyclonal NRN1 antibody detects NRN1 protein in vitro and in vivo at molecular weights that suggest NRN1 forms a homodimer. NRN1 protein abundance is comparable among controls and primary tauopathy cases, as well as Tau P301S mice and non‐transgenic littermates at 3 and 9 months.
